Evidence map›Paper›PMID 38258767›Full record

ReviewCurrent pharmaceutical biotechnology2024

The Impact of miR-122 on Cancer.

Shijie Wu, Yiwen Wu, Sijun Deng, Xiaoyong Lei, Xiaoyan Yang

Open access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shijie WuSchool of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang, Hunan, P.R. China.
Yiwen WuSchool of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang, Hunan, P.R. China.
Sijun DengSchool of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang, Hunan, P.R. China.
Xiaoyong LeiSchool of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang, Hunan, P.R. China.
Xiaoyan YangSchool of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang, Hunan, P.R. China.ORCID 0000-0002-7591-7505
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MiRNAs are confirmed to be a kind of short and eminently conserved noncoding RNAs, which regulate gene expression at the post-transcriptional level via binding to the 3'- untranslated region (3'-UTR) of targeting multiple target messenger RNAs. Recently, growing evidence stresses the point that they play a crucial role in a variety of pathological processes, including human cancers. Dysregulated miRNAs act as oncogenes or tumor suppressor genes in many cancer types. Among them, we noticed that miR-122 has been widely reported to significantly influence carcinogenicity in a variety of tumors by regulating target genes and signaling pathways. Here, we focused on the expression of miR-122 in regulatory mechanisms and tumor biological processes. We also discussed the effects of miR-122 dysregulation in various types of human malignancies and the potential to develop new molecular miR-122-targeted therapies. The present review suggests that miR-122 may be a potentially useful cancer diagnosis and treatment biomarker. More clinical diagnoses need to be further launched in the future. A promising direction to improve the outcomes for cancer patients will likely combine miR-122 with other traditional tumor biomarkers.

Indexed as

MicroRNAsNeoplasmsAnimalsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansBiomarkers, TumorMicroRNAsMIRN122 microRNA, humanbiological processesbiomarkercancermiR-122molecular mechanismpolyadenylation signal.tumorigenesis

Identifiers

PMID38258767
OpenAlexW4391137213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.